As postoperative pain management continues to evolve toward safer and more multimodal strategies, clinicians are seeking non-pharmacologic modalities capable of reducing opioid exposure without compromising analgesia or recovery outcomes. A recent peer-reviewed study published in the Journal of Clinical Medicine provides encouraging evidence that the NeuroCuple® device—a passive, battery-free nano-capacitive patch—may serve as a meaningful adjunct in early postoperative care.
🔗 Study link: https://www.mdpi.com/2077-0383/12/23/7394
Study Design Summary
Conducted at UPMC Shadyside, this prospective, randomized, open-label pilot trial evaluated the NeuroCuple® device in opioid-naïve adults undergoing unilateral primary TKA or THA.
Key elements:
Participants randomized postoperatively to:
Standard multimodal analgesia alone, or
Standard care + two NeuroCuple® devices applied to the anterior thigh
Pain was assessed using the Numerical Rating Scale (NRS) at rest and during movement
Opioid consumption was converted into oral morphine equivalents (OME)
Secondary endpoints included opioid prescription refills through postoperative day (POD) 30, patient satisfaction, and adverse events
A total of 69 patients were enrolled (38 NeuroCuple®, 31 control), the majority undergoing TKA.
Clinical Outcomes
1. Significant Reduction in Pain at Rest
During POD 1–3, the NeuroCuple® group demonstrated:
34% reduction in AUC pain scores at rest
Mean AUC: 6.3 (NeuroCuple®) vs. 9.5 (control)
p = 0.018, indicating statistical significance
This reduction occurred during the period when postoperative pain is typically at its peak and most challenging to control.
2. Reduced Opioid Refill Requests Through Day 30
A key clinical finding was the marked decrease in opioid refill requests:
26% in the NeuroCuple® group
55% in the control group
p = 0.016
Given growing concerns around persistent postoperative opioid use, use and prescription opioid-related dependence after surgery, this finding suggests a clinically relevant impact on downstream opioid exposure.
3. Comparable In-Hospital Opioid Consumption
Although the NeuroCuple® group used slightly fewer opioids during POD 1–3 (63.6 mg OME vs. 70.2 mg OME), the difference was not statistically significant (p = 0.37).
However, the reduction in refill requests suggests benefits may emerge more clearly after discharge.
4. No Device-Related Adverse Events
Across all participants:
No skin reactions
No burns or electrical effects
No tolerance or placement-related issues
The device demonstrated an excellent safety profile.
How the NeuroCuple® Fits Into Clinical Practice
A Passive, Non-Pharmacologic Adjunct
The NeuroCuple® is a passive nano-capacitive array designed to stabilize local electrical disturbances associated with tissue trauma. It does not deliver electrical stimulation, heat, cold, or chemicals, making it easy to integrate into:
Enhanced Recovery After Surgery (ERAS) pathways
Multimodal analgesia protocols
Outpatient and ambulatory surgical settings
Compatible With Existing Standards of Care
The device can be:
Applied by nursing staff
Worn continuously for multiple days
Used concurrently with cryotherapy, pharmacologic agents, and physical therapy
Utilized in patients with contraindications to systemic analgesics
Potential to Reduce Opioid Burden
With refill requests reduced by half, the technology may play a role in:
Reducing prolonged postoperative opioid use
Minimizing exposure among opioid-naïve populations
Supporting prescriber stewardship programs
Limitations of the Study
The authors noted several limitations:
Pilot scale with a modest sample size
Open-label design (no sham/placebo device control)
Larger representation of TKA vs. THA patients
Postoperative follow-up limited to 30 days
Mechanism of action requires further elucidation
These limitations support—but do not diminish—the value of the preliminary evidence.
Implications for Clinical Adoption
For clinicians, the NeuroCuple® offers:
1. A low-risk adjunct that can be added without workflow disruption
Its passive design and safety profile allow seamless integration into existing protocols.
2. Evidence-based potential to improve immediate postoperative pain
The significant reduction in pain at rest may translate into better mobility, earlier participation in rehabilitation, and improved patient satisfaction.
3. Potential to reduce opioid utilization after discharge
This is clinically meaningful given the risk of persistent opioid use after arthroplasty.
4. Excellent tolerability
No adverse events were reported, an important consideration for postoperative patients with fragile skin or high comorbidity burdens.
What This Means for nCAP Medical
A Validated Proof-of-Concept
This study provides high-quality evidence supporting the NeuroCuple® as a viable non-pharmacologic adjunct in postoperative pain management.
Credibility With Clinicians and Hospital Systems
Peer-reviewed data from a reputable institution helps strengthen:
Clinical trust
Pathways to adoption
Inclusion in ERAS protocols
Opportunities for interdisciplinary research
Catalyst for Larger Clinical Trials
Combined with the ongoing NIH-funded study, this trial supports:
Expansion to multi-center, sham/placebo-controlled randomized controlled trials
Opportunities for regulatory review and reimbursement pathways
Applications in additional surgical and non-surgical pain settings
Support for Broader Medical Integration
The NeuroCuple® is uniquely positioned as:
A reusable, drug-free technology
An ultra-low-risk adjunct with high patient acceptability
A scalable solution that aligns with opioid stewardship initiatives
Conclusion
The 2023 UPMC study provides meaningful evidence that the NeuroCuple® device can reduce early postoperative pain and significantly lower downstream opioid refill rates—without adverse effects or workflow complexity.
For clinicians seeking to enhance recovery, minimize opioid exposure, and improve patient experience, the NeuroCuple® represents a promising addition to multimodal pain-management strategies.